Sign up for the QMED & MD+DI Daily newsletter.
Public Outcry Cancels Meeting
FDA has canceled the Blood Products Advisory Committee meeting scheduled for today because of calls for it to be made open to the public. At issue, reports the Boston Globe, is the blood substitute made by Biopure Corp. (Cambridge, MA), the trial of which calls for it to be given to trauma patients in ambulances without their consent.
July 14, 2006
1 Min Read
.svg?width=1280&auto=webp&quality=95&format=jpg&disable=upscale "Public Outcry Cancels Meeting")
The outcry over the protocol has led Public Citizen to sue FDA to make the panel meeting public. FDA has placed Biopure's application on hold. The meeting has been postponed until FDA, the company, and the Navy (which is involved in the product's development) can figure out a way to hold a public meeting without compromising trade secrets. Such is the way of democracy.
You May Also Like
.png?width=700&auto=webp&quality=80&disable=upscale)
.png?width=700&auto=webp&quality=80&disable=upscale)